Scott Power: ASX health stocks dip but it was a good news week for EMVision
ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26%
EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial
First Japan site opens for Dimerix's phase III clinical trial of DMX-200 in rare kidney disease
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick.
Power said that, while healthcare markets were down this week, broader markets remained elevated with things starting to look more positive at the halfway mark of a thus-far volatile 2025.
US President Donald Trump's trade and health policies have been impacting the sector throughout the year.
At about lunchtime on Friday the S&P/ASX 200 Health Care index was down 0.82% for the past five days, while the benchmark ASX 200 rose 1.26% for the same period.
"The broader market is up this week and May was a reasonably good month," he said.
"We are coming up to June 30 and the end of financial year so there will be some tax-loss selling coming through across various portfolios.
"June tends to be a weaker month as investors look to clean up their portfolio, while July seasonally tends to be a stronger month and there is potentially some good value out there across the smaller names which really haven't done too much for the last couple of years."
Ramsay CEO joins EMVision board, trial expands
EMVision Medical Devices (ASX:EMV) has had two major announcements this week including the appointment of Ramsay Health Care (ASX:RHC) CEO Carmel Monaghan as non-executive director and broadening of a pivotal trial for its emu bedside brain scanner, which is designed to rapidly diagnose stroke.
Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades.
"She is highly regarded and will bring a lot of credibility and contacts into the business," Power said.
He said EMvision was also making good progress with the activation of its third US site, Mount Sinai Hospital in New York, scheduled for this month.
Activation of its second Australian site, Liverpool Hospital in Sydney, has also been in progress this week.
Five world-leading hospitals in stroke care are now taking part in EMVision's pivotal trial with a sixth set to be activated shortly.
The pivotal (validation) trial is designed to support US Food and Drug Administration (FDA) de novo (new device) clearance of the emu point-of-care brain scanner device.
"The expectation is that they will get approval sometime in 2026," Power said.
Power's Powerplay: Big year for Dimerix
Dimerix (ASX:DXB) is Power's stock of the week after announcing it had opened the first trial site in Japan for its ACTION3 phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease.
Opening of Japan's first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million (~A$4.3m) to Dimerix from FUSO Pharmaceutical Industries Ltd, its exclusive licensee of DMX-200 for FSGS in Japan.
FUSO is one of four regional licensing deals executed for DMX-200, which collectively provide up to ~$1.4bn in total upfront payments and potential milestone payments, plus royalties on net sales.
FSGS is a serious kidney disease that causes progressive scarring, leading to permanent damage and, ultimately, end-stage kidney failure – often requiring dialysis or a transplant.
It affects adults and children and no treatments are currently approved specifically for the condition anywhere in the world, affecting overall prognosis.
As a result, DMX-200 has received orphan drug designation in both the US and Europe, along with the UK's equivalent designation under the Innovative Licensing and Access Pathway (ILAP).
Dimerix last year reported positive interim results from the ACTION3 trial, showing DMX-200 was performing better than placebo in reducing proteinuria with no safety concerns to date. Full enrolment in the ACTION3 study is expected by the end of 2025 with a further blinded interim analysis planned.
"It's going to be a big year for Dimerix," Power said.
Mayne Pharma takeover deal far from over
Adelaide-headquartered pharmaceutical company Mayne Pharma (ASX:MYX) is continuing to do battle with its US-based suitor Cosette Pharmaceuticals after announcing on Wednesday it had received a notice "purporting to terminate" the $7.40 per share offer worth more than $600 million.
The withdrawal comes after Cossette asserted that a "material adverse change" had occurred, and consequently freeing Cosette from its obligations under the scheme implementation deed (SID).
The announcement sent the stock lower and came hours after Mayne put out another one telling the market it had not received a notice of termination, which sent its shares higher.
On Thursday Mayne put out another announcement saying the scheme meeting would go ahead on June 18, as scheduled with the stock rising more than 7%.
"Mayne Pharma directors continue to unanimously recommend that vote in favour of the scheme resolution at the scheme meeting, in the absence of a superior proposal," said chairman Frank Condella.
However, the company needs a court decision to affirm its view that the "material adverse change" were not, in fact, material.
"There is a fair bit more water to flow under the bridge with this one and it just looks very messy at the moment," Power said.
ReNerve enters partnership to expand product range
Biotech company ReNerve (ASX:RNV) this week announced it had entered a strategic partnership with US-based Berkeley Biologics LLC to develop and commercialise two new complementary tissue-based product ranges.
The first range addresses the need for human dermal tissued, deeper layers of the skin often sourced from donors.
The second product range will provide amniotic tissue products, which are known for their regenerative and healing properties.
The products are set to be produced at Berkeley Biologics' California facility and launch before the end of CY25.
ReNerve said the new products represent a natural extension of its existing sales activities, leveraging the same sales network and continuing to target the same surgeon and hospital customer base.
The company said surgeons could incorporate additional tissue grafts when treating nerve injuries, enabling them to address both the damaged nerve and any associated trauma.
"It is a strong indication that they're trying to build their sales momentum by expanding the product offering to the surgeons," Power said.
"Sales are expected to grow over subsequent quarters."
The views, information, or opinions expressed in the interview in th is article are solely those of the interviewee and do not represent the views of Stockhead.
Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
The best thing that's ever happened in a business class cabin
Not since the advent of the lie-flat bed, has a business class offering been more of a gamechanger. OK, this might only be true if you've got as much of a sweet tooth as I do, but hear me out – you're cruising along at 38,000 feet, feet up on your glorious recliner, full of your gourmet dinner, when something absolutely glorious, and unexpected, comes rattling down the aisle. An ice cream sundae cart! With all the trimmings! On a plane! I rest my case. United Airlines is famous for this particular in-flight miracle, which has reached icon status among its passengers. After your meal, the cart comes along, offering to adorn your vanilla or chocolate ice cream scoop with hot fudge sauce, whipped cream, slivered toasted almonds, M & Ms and a cherry on top. If there's a better food experience on a plane, I haven't had it. New cabins Last month, United Airlines unveiled its new United Elevated interior, which includes sliding privacy doors for all business class seats, and a brand new studio suite experience. There are eight of the new seats in each upgraded cabin, located at the front of each business class section. They are 25 per cent larger than the standard business offering and offer even more privacy. I flew from Sydney to LA on the standard Polaris service, here's how it went down. Baggage Like most business class offerings, your ticket includes two free checked bags, up to 32kg each, which is a challenge I was unable to meet, with my puny 22kg offering. You're also entitled to Premier Access, which is essentially a priority check-in lane, and the promise of seeing your bags faster on the other side with priority bag handling. Lounge Polaris customers also get access to United Polaris lounges, where they are available (currently there are six, Chicago O'Hare, Houston Intercontinental, LAX, New York Newark, San Francisco and Washington Dulles). Don't worry, if there's no Polaris Lounge at your departure airport, you will get access to a partner lounge of your choice. I used the Polaris Lounge at LAX. It features deluxe shower rooms with Therabody products, an a la carte restaurant (order the famous burger and the skillet cookie, even if you're not hungry, trust me on this) as well as a buffet for lighter meal options. If you're already tired, there's a private rest area with daybeds, soft lighting and white noise to help you rest and relax The seats Like many business class offerings, the staggered 1-2-1 seat configuration means every seat is an aisle seat, but window seats are definitely the pick of the bunch. But not all window seats are created equal – to enable a full lie-flat experience, the seats are offset, with one being right next to the window, the next being closer to the aisle and so forth. This makes seats 1L or 9L superior choices, as they are both front of their respective parts of the cabin, closest to the windows and with the most privacy and least disturbance from the aisle. There was lots of legroom, as expected, and top notch extras, including noise-reducing headphones, bedding from Saks Fifth Avenue, premium toiletries and premium mattress toppers available on request (please, tell me, who is not requesting a complimentary 'mattress cloud'?). Food In addition to the expected champagne on arrival, the meals were excellent on my flight. The main meal is an event, with warmed mixed nuts, a main you can pre-order before you fly (I chose roasted salmon with hollandaise and pearl couscous) salad, bread and the aforementioned sundae. Still hungry after your movie is over? They offer midnight snacks, including an extremely melty grilled cheese sandwich, available anytime, and a snack bar you can help yourself to. The app It can be hard to stand out in a saturated airline market where most offerings are variations on the same thing, but United's app is where it truly shines. I've never come across such an efficient and user-friendly airline app experience. You can obviously plan and book using it, but it's once you arrive at the airport that it comes into its own. My gate changed, no worries, I got a notification. Boarding about to start? told me that too. In-flight I was updated about changes to our arrival time and upon landing, it knew my bag was about to come out onto the carousel before it was visible. There's also a terminal guide, meal and seat choices and delay and cancellation options but it's the real-time notifications, taking some of the stress and uncertainty out of travel, that gets my vote.
News.com.au
2 hours ago
- News.com.au
Commonwealth Bank soars past $300 billion value but experts have concerns
Commonwealth Bank shocked the world this week when its value topped an eye-watering $300 billion, dwarfing even Wall Street's biggest banks and outpacing its Australian competitors. For some perspective, the staggering rise of CBA puts it well above the combined value of two of the big four banks in Australia — Westpac and National Australia Bank. It also becomes an outlier as the first ever ASX-listed company to be valued at more than $300 billion and is the most expensive bank stock in the history of the world thanks to a 49 per cent rise in the past 12 months. But experts say not all is as it seems. One says CBA is completely overvalued and the $300 billion figure ignores 'anemic earnings growth'. Share trader author Alan Hull told Commonwealth Bank shares are 'a risky share to be buying'. 'Smart money is not buying CBA,' he said. 'It's seriously overvalued. It's earnings growth is anemic. The current divident yield is 3.74 per cent including tax imputations. 'It's overpriced, which means it's a risky share to be buying and it's only yielding 3.74 per cent.' He credits CBA's exponential rise to a 'popularity competition'. 'The share price is going up simply because the share price is going up. If you look at the price of CBA shares, it's exponential. It's price feeding on price. I buy CBA, I tell you about CBA, price goes up 10 per cent. You buy CBA, price goes up another 10 per cent and you tell all your mates. 'We've also got new money coming in. Dumb money starts coming into the market and what do they buy? All the new dumb money is buying CBA. That's all it is. There's nothing going on here that is a secret.' He said all the major shares are running 'because that's all that dumb money knows'. 'That's the moron portfolio and at the top of the moron portfolio sits CBA.' So what happens now? Mr Hull has a prediction. 'It'll get to $200 a share and you'll probably see a correction,' he said. 'Do I think it could go up? Yeah. 'But a big correction is coming. It's literally 50 per cent overpriced. So when it corrects, it's going to be a big correction. It's trading a fair distance away from its underlying fundamentals.' Chief economist at AMP, Shane Oliver, told Commonwealth Bank is benefiting from a number of different factors — one of which being a less hostile US President Donald Trump. 'Its rise lately has mostly been driven by the same factors as the broader market, (including) an easing in concerns about Trump's tariffs and increased expectations for interest rate cuts, which are seen as positive for the banks,' he said. 'That said there also appears to be an element of momentum by which past relatively strong performance appears to be driving expectations that this will continue, resulting in ongoing strong relative demand for its shares.' Mr Hull said CBA is doing nothing different to the other big banks in Australia 'apart from being more popular'. 'It's a popularity competition,' he said. 'CBA is first, ANZ is second and Westpac and NAB are third.' In its latest results, Commonwealth Bank made $9.48 billion after tax, while Westpac made $7 billion, NAB made $6.96 billion and ANZ made $6.53 billion. Kevin Doodney, an Australian housing futurist at the High Yield Property Group, told in April that 'the big four Australian banks make up four of the eight most profitable banks in the world'. 'They are making that money from a population of just 27 million people. There's 8 billion people out there, for Christ's sake. 'What the Australian public needs to ask is, how on Earth can that be possible? Because, I think the Australian people are going to look at that and go, nah, that's not possible.' Mr Doodney said successive federal governments and the Reserve Bank of Australia (RBA) have justified these profits made in the banking sector because they have called for a 'robust banking system'. 'I'm calling bulls**t on that, because my attitude is that, you know, for the first time in history, affordable housing is becoming a serious issue for any government, and you've got to look at who's making the money out of that, between either the government themselves or the banking system,' he said.
ABC News
2 hours ago
- ABC News
Coalition sticks to defence spending pledge but won't say how it'll pay for it
The Coalition remains committed to lifting defence spending to 3 per cent of GDP but won't detail where the money will come from, as the shadow finance minister suggested the opposition would be open to considering broader tax reform. Prime Minister Anthony Albanese is expected to meet with Donald Trump on the sidelines of G7 summit next week, amid pressure from the United States to increase defence spending from the current level of 2.04 per cent to to 3.5. Trade Minister Don Farrell on Sunday said the government was committed to a "significant uplift in the amount of defence spending". "We're focused on what Australia needs to do and we'll make our decisions based on what's in our national interest," he told Sky News. The Coalition went to the election promising to earmark an additional $21 billion for the military between now and 2030, almost double what Labor had pledged. Appearing on Insiders on Sunday, Shadow Finance Minister James Paterson said the Coalition's target of 3 per cent of GDP in a decade had not changed since the party's devastating election loss last month. "The exact profiling of that increase is something that we'll determine through the policy process and closer to the next election. We'll be completely up front and transparent about that," he said. "But yes, we have an objective of reaching the 3 per cent of GDP because we think it is in our national interest." Senator Paterson said the Coalition had three years to outline where that additional funding would go, but listed some potential areas for investment as recruitment and retention, a munitions stockpile, northern military bases, air and missile defence and drones. "There is no shortage of good things we could spend on that would increase our ability to defend ourselves and safeguard our sovereignty," he said. But he would not be drawn on where the money to pay for the increase would come from, saying that work would occur over the coming years. Senator Paterson did suggest the opposition was open to a discussion about the way superannuation is taxed, despite its rejection of the government's plan to double the tax on super balances above $3 million from 15 to 30 per cent. "We're happy to contemplate tax reform. We're happy to talk to the government about tax reform. But we are not interested in increasing taxes, because I don't think that that is what the Australian economy needs right now," he said. "If the government was genuinely serious about a broad-based tax reform process, then we'd be up for that conversation. Now, the government has to take the first steps there." US Defense Secretary Pete Hegseth asked Defence Minister Richard Marles to increase spending to 3.5 per cent of GDP "as soon as possible" on the sidelines of a dialogue in Singapore this week, according to a statement from the US Department of Defense. Mr Hegseth had previously made similar requests, but it was the first time the administration nominated an exact figure. Negotiations with the United States over Mr Trump's 10 per cent tariffs on Australian exports continue, with the subject likely to dominate the anticipated meeting between Mr Albanese and Mr Trump. Access to Australia's critical minerals has been put forward as a potential bargaining chip as Australia continues to push for an exemption. The Coalition had previously said they would oppose Labor's plan to acquire stockpiles of critical minerals from commercial projects, to be held in a national reserve and made available to domestic industry and international partners. But Senator Paterson told Insiders it "might be necessary" for the government to support the mining and processing of critical minerals. "We're very happy to see what the government is proposing here. I can't commit to it in principle without having seen the details, but we're certainly open to it," Senator Paterson said. "Any sensible steps that represent an economic opportunity for Australia and an opportunity for us to demonstrate that we are a good alliance partner of the United States is something that we would offer bipartisan support to." Mr Farrell said Australia had offered the United States "an expanded arrangement in regards to critical minerals" as part of efforts to secure an exemption from the tariffs, which came into force in April. The trade minister met with his American counterpart, trade representative Jamieson Greer, in Paris last week, where he said he made clear that Australia wanted "all of the tariffs removed, not just some of them". "The position I put to Jamieson Greer is that the tariffs the United States has imposed on Australia are unjustified."
